Who Is Not a Good Candidate for Stem Cell Therapy?

Stem cell and regenerative cell therapies are often marketed as low-risk options suitable for almost anyone, but that framing is misleading. A small number of stem cell and stem-cell-derived products are FDA-approved and genuinely appropriate for specific patients — most notably cord blood stem cells for blood-forming disorders and, as of December 2024, the mesenchymal stromal cell drug Ryoncil (remestemcel-L) for children with steroid-refractory acute graft-versus-host disease. Outside those narrow, evidence-backed uses, candidacy depends heavily on a patient's underlying health, the specific condition being treated, and whether real evidence supports the claim being made. This article walks through the medical contraindications, evidence gaps, and financial red flags that should make a patient — or their doctor — pause before proceeding.

Active Cancer or a Recent History of Malignancy

Patients with active cancer, or a recent history of one, are generally considered poor candidates for unproven stem cell injections. The concern isn't hypothetical: a 2024 review in Oncogene documents that mesenchymal stromal cells (MSCs) can secrete growth factors such as IL-6, HGF, and FGF, transfer pro-tumor signals via extracellular vesicles, and even help cancer cells acquire stem-cell-like properties — mechanisms that, in a patient with existing malignant or pre-malignant cells, could theoretically fuel tumor growth rather than healing tissue. This is a real reason oncologists urge caution, even though a widely cited 2012 systematic review and meta-analysis (SafeCell, covering 36 trials and over 1,000 patients) found no statistically significant increase in malignancy among patients who received MSC therapy in controlled studies. The honest picture is nuanced: the clinical signal so far is reassuring, but the theoretical mechanism is well-documented, so most legitimate providers exclude patients with active or recent cancer from elective regenerative procedures — while FDA-approved cell therapies used within cancer treatment itself, like stem cell transplants for blood cancers, remain a completely different, tightly regulated category.

Active Infection, Pregnancy, and Severe Organ Dysfunction

Any active systemic or local infection is a standard exclusion, since introducing cells — or the injection process itself — into an infected site raises the risk of seeding bacteria more deeply or triggering sepsis. Pregnant and breastfeeding patients are also routinely excluded from investigational stem cell procedures, largely because there is no adequate safety data on fetal or infant exposure. Patients with severe kidney, liver, heart, or lung dysfunction face added risk too: many procedures involve sedation, contrast agents, or cell products cleared through organs that may already be compromised, and the inflammatory response some patients experience after infusion (transient fever appeared significantly more often after MSC infusion in the SafeCell analysis) can be harder for a frail patient to tolerate.

Bleeding Disorders and Blood-Thinning Medications

Most stem cell procedures involve harvesting cells (often from bone marrow or fat) and then injecting them, frequently under imaging guidance into joints or soft tissue. Patients with clotting disorders, or those on anticoagulant or antiplatelet medications, face a higher risk of bleeding or hematoma at both the collection and injection sites. This is typically manageable — many patients can pause certain blood thinners under a physician's supervision — but it needs to be addressed explicitly, not glossed over, before any procedure is scheduled.

Autoimmune Disease: A More Nuanced Picture

Autoimmune conditions occupy a genuinely gray zone. MSCs have well-documented immunomodulatory properties, and early-phase trials in conditions like Crohn's disease, lupus, and rheumatoid arthritis have generally reported good short-term safety, according to a 2015 review in Stem Cells and Development. But that same review notes that inflammatory disease environments can alter how MSCs behave — for example, reversing their immunosuppressive effects in some models — and that MSCs are short-lived after infusion, leaving real uncertainty about durability and flare risk in individual patients. This is exactly the kind of condition where enrolling in a registered, IRB-approved clinical trial (searchable at ClinicalTrials.gov) is the more defensible path than a one-off injection at a direct-to-consumer clinic.

Allergy to Product Components

Because many cell products are processed or expanded using animal-derived serum, antibiotics, or other additives, patients with known allergies to these components need a full ingredient disclosure before treatment. Legitimate providers can and should supply this; an inability or unwillingness to do so is itself a warning sign.

When There's No Evidence Base for Your Condition

Even when a patient's general health poses no red flags, candidacy still depends on whether evidence supports stem cell treatment for their specific condition. The FDA has been explicit that no cell-based regenerative product has been approved for COVID-19, ALS, Alzheimer's, Parkinson's, autism, stroke, chronic pain, or general orthopedic conditions like arthritis and tendonitis — the very conditions most often marketed by direct-to-consumer clinics. A patient can be medically eligible in every other sense and still not be a good candidate, simply because the evidence for that use doesn't exist yet outside of registered clinical trials.

Chasing a Cure Where Only Modest Benefit Is Realistic

A separate, often-overlooked candidacy issue is expectation-setting. Some patients with degenerative joint disease or chronic pain are reasonable candidates for procedures with modest, non-curative goals — symptom reduction, delayed progression — but are sold the therapy as a cure or a substitute for surgery. Spending thousands of out-of-pocket dollars (these procedures are rarely covered by insurance) chasing a "cure" that the evidence doesn't support isn't a medical contraindication, but it's a legitimate reason to reconsider candidacy, especially for patients on fixed incomes or with more effective, established treatments available.

Red Flags: Clinics That Claim Everyone Qualifies

The ISSCR's Patient Handbook is direct about this: real treatments come with real limits, and a clinic that "claims there is no risk," treats one product as a cure-all for unrelated diseases, or relies on testimonials instead of published, peer-reviewed evidence is not practicing evidence-based medicine. This isn't theoretical. A Pew Charitable Trusts analysis identified 360 documented adverse-event cases tied to unapproved stem cell interventions between 2004 and 2020, including at least 20 deaths, 9 cases of partial or complete blindness, and 104 hospitalizations. The best-known blindness cases, published in the New England Journal of Medicine in 2017, involved three women who suffered severe vision loss after a Florida clinic injected unproven autologous "stem cells" into both of their eyes for macular degeneration in a single visit — treating both eyes at once, and offering the procedure with essentially no meaningful screening, are themselves red flags. If a clinic tells you that you're a candidate before reviewing your full medical history, or says the treatment works for nearly any diagnosis, that confidence should be a warning, not a reassurance.

Bottom Line

Being ruled out isn't a failure of the science — it's the science working as it should. Before agreeing to any stem cell procedure, ask your provider three things: What published, peer-reviewed evidence supports this specific treatment for my specific condition? Is this procedure part of an FDA-regulated clinical trial or an FDA-approved product, and can you show me the IRB approval or BLA if so? And what, realistically, should I expect — cure, improvement, or no measurable change? A provider who can't answer clearly, or who insists you're a good candidate without a real evaluation, is telling you something important about the treatment itself.